Publications by authors named "A Archimbaud"
Article Synopsis
- About 50% of melanoma cases have the BRAF V600 mutation, which activates the MAP kinase pathway and responds well to BRAF inhibitors, but the effectiveness usually lasts only about 6 months.
- A study involving nine patients who previously benefited from BRAF inhibitors found that some patients had positive responses when treated again after disease progression.
- Findings suggest that alternating treatments, such as BRAF inhibitors following intercurrent treatments like ipilimumab, may be beneficial and merit further investigation in clinical trials.
Ultrasound-guided core needle biopsy of superficial lymph nodes: an alternative to fine-needle aspiration cytology for the diagnosis of lymph node metastasis in cutaneous melanoma.
Melanoma Res
December 2015
To investigate the diagnostic value of ultrasound-guided core needle biopsy (US-CNB) in suspected cases of lymph node metastasis from cutaneous melanoma. All patients with cutaneous melanoma followed in Saint-Louis Hospital between 2006 and 2010 who underwent US-CNB for suspicion of melanoma lymph node metastasis were reviewed retrospectively. Histopathological results of US-CNB samples were classified as melanoma, other malignancy, suspicious, inadequate, or benign.
View Article and Find Full Text PDFObjectives: To evaluate the prognostic value of melanocytic differentiation antigens and angiogenesis biomarkers in sentinel lymph nodes (SLNs) with melanoma micrometastases.
Design: Prognostic study of an inception cohort.
Setting: Academic research.
[Hypersensitivity to dacarbazine in patients with metastatic malignant melanoma].
Ann Dermatol Venereol
February 2006
Background: Dacarbazine (DTIC) is the first-line chemotherapy for metastatic malignant melanoma without cerebral metastasis. Its clinical and hematological safety is usually good. Hypersensitivity in hepatic failure patients is the most serious side effect described.
View Article and Find Full Text PDF